Fate Therapeutics (FATE) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
March 5, 2018 4:01 PM ESTInitial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow
All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival
Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated in Support of Landmark IND Filing
Breakthrough Generation of Universal CAR T cells from Clonal Master iPSC Line Achieved under MSK Collaboration
Preclinical Data of FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrate Target-specific Anti-tumor Activity
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE)... More
